These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 2972667

  • 1. The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
    Newman HF, Ward R, Workman P, Bleehen NM.
    Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1073-83. PubMed ID: 2972667
    [Abstract] [Full Text] [Related]

  • 2. A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
    Bleehen NM, Newman HF, Maughan TS, Workman P.
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1093-6. PubMed ID: 2539346
    [Abstract] [Full Text] [Related]

  • 3. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
    Newman HF, Bleehen NM, Workman P.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1113-6. PubMed ID: 2943709
    [Abstract] [Full Text] [Related]

  • 4. Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
    Newman HF, Bleehen NM, Ward R, Workman P.
    Int J Radiat Oncol Biol Phys; 1988 Sep; 15(3):677-84. PubMed ID: 2843488
    [Abstract] [Full Text] [Related]

  • 5. The combination of multiple doses of etanidazole and pimonidazole in 48 patients: a toxicity and pharmacokinetic study.
    Bleehen NM, Maughan TS, Workman P, Newman HF, Stenning S, Ward R.
    Radiother Oncol; 1991 Sep; 20 Suppl 1():137-42. PubMed ID: 1826962
    [Abstract] [Full Text] [Related]

  • 6. Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508).
    Maughan TS, Newman HF, Bleehen NM, Ward R, Workman P.
    Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1151-6. PubMed ID: 2140825
    [Abstract] [Full Text] [Related]

  • 7. Radiosensitization by the combination of etanidazole (SR-2508) and pimonidazole (Ro 03-8799) in human tumor xenografts.
    Taghian A, Lespinasse F, Guichard ME.
    Int J Radiat Oncol Biol Phys; 1991 Nov; 21(6):1535-40. PubMed ID: 1834621
    [Abstract] [Full Text] [Related]

  • 8. Additivity of radiosensitization by the combination of SR 2508 (etanidazole) and Ro 03-8799 (pimonidazole) in a murine tumor system.
    Honess DJ, Wasserman TH, Workman P, Ward R, Bleehen NM.
    Int J Radiat Oncol Biol Phys; 1988 Sep; 15(3):671-5. PubMed ID: 2971028
    [Abstract] [Full Text] [Related]

  • 9. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
    Coleman CN, Wasserman TH, Urtasun RC, Halsey J, Noll L, Hancock S, Phillips TL.
    Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):389-93. PubMed ID: 2154420
    [Abstract] [Full Text] [Related]

  • 10. Initial results of a phase I trial of continuous infusion SR 2508 (etanidazole): a radiation therapy oncology group study.
    Coleman CN, Noll L, Howes AE, Harris JR, Zakar J, Kramer RA.
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1085-7. PubMed ID: 2522919
    [Abstract] [Full Text] [Related]

  • 11. Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a Radiation Therapy Oncology Group study.
    Coleman CN, Noll L, Riese N, Buswell L, Howes AE, Loeffler JS, Alexander E, Wen P, Harris JR, Kramer RA.
    Int J Radiat Oncol Biol Phys; 1992 Apr; 22(3):577-80. PubMed ID: 1531217
    [Abstract] [Full Text] [Related]

  • 12. Hypoxic cell radiosensitizers: expectations and progress in drug development.
    Coleman CN.
    Int J Radiat Oncol Biol Phys; 1985 Feb; 11(2):323-9. PubMed ID: 3156109
    [Abstract] [Full Text] [Related]

  • 13. A comparison of radiosensitization by etanidazole and pimonidazole in mouse tumors.
    Stone HB, Hirst VK, Cribbs R, Luu YH, Brown JM.
    Int J Radiat Oncol Biol Phys; 1991 May; 20(5):987-95. PubMed ID: 1827089
    [Abstract] [Full Text] [Related]

  • 14. Logistics in designing clinical trials for etanidazole (SR 2508): an RTOG experience.
    Lee DJ, Phillips TL, Coleman CN, Cosmatos D, Davis LW, Wasserman TH, Marcial VA, Rubin P.
    Int J Radiat Oncol Biol Phys; 1992 May; 22(3):569-71. PubMed ID: 1531215
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of 2-nitroimidazole hypoxic cell radiosensitizers in rodent peripheral nervous tissue.
    Sasai K, Shibamoto Y, Takahashi M, Ito T, Nishimoto S, Abe M.
    Int J Radiat Biol; 1990 May; 57(5):971-80. PubMed ID: 1970998
    [Abstract] [Full Text] [Related]

  • 16. Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.
    Coleman CN, Urtasun RC, Wasserman TH, Hancock S, Harris JW, Halsey J, Hirst VK.
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1749-53. PubMed ID: 6237086
    [Abstract] [Full Text] [Related]

  • 17. Sensitization by SR-2508 plus Ro 03-8799.
    Stone HB, Luu YH, Lam KN.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1097-100. PubMed ID: 2943707
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A comparison of the ability of some radiosensitizers undergoing clinical trials to act as chemosensitizers.
    Hinchliffe M, McNally NJ.
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1635-40. PubMed ID: 6237081
    [Abstract] [Full Text] [Related]

  • 20. The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer.
    Coleman CN, Buswell L, Noll L, Riese N, Rose MA.
    Int J Radiat Oncol Biol Phys; 1992 Sep; 22(3):565-8. PubMed ID: 1310497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.